Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 133

Results For "IP"

11175 News Found

Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study
News | May 14, 2026

Wegovy delivers consistent weight loss & heart benefits for women across menopause: Novo Nordisk study

Nearly one in five women worldwide are now living with obesity


Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
News | May 14, 2026

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros


Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push
News | May 14, 2026

Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push

Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support


Pfizer scores landmark EU approval for  hemophilia drug HYMPAVZI
Drug Approval | May 14, 2026

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy


Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation
Clinical Trials | May 14, 2026

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies


AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX
interviews | May 13, 2026

AI will eliminate 70-80% of current pharma commercial processes: Dushyant Sapre, Founder and CEO, SwishX

We are building an AI-native operating system for pharma sales and distribution


Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy
News | May 13, 2026

Actio Biosciences launches Phase 1b/2 trial for ultra-rare pediatric epilepsy therapy

The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process